 |
Prospector
Profile
208-13
|
| |
| Hemagen Diagnostics, Inc. |
NAICS |
339100 |
| 9033 Red Branch Road
Columbia, MD 21045 |
Description |
Medical Equipment Mfg. |
| (443) 367-5500 |
Employees |
31 |
| http://www.hemagen.com/ |
Revenue |
(mil) |
4.4870 |
| |
Income |
(mil) |
-0.8490 |
| |
Assets |
(mil) |
4.1350 |
| |
Liability |
(mil) |
5.6300 |
| |
(for the year ended 2007-09-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Hemagen Diagnostics, Inc. reported a net loss of $849,931 on net sales of $4,487,236 for the year ended September 30, 2007, compared with net income of $312,926 on net sales of $4,775,216 for the year ended September 30, 2006. The Company's consolidated balance sheet at September 30, 2007, showed $4,135,091 in total assets and $5,630,856 in total liabilities, resulting in a $1,495,765 stockholders' deficit. It also has an accumulated deficit of $24,353,140 as of September 30, 2007.
|
| |
|
Intellectual Property:
Hemagen acquired a patent protected rotor-based technology for use in the Analyst in 1998. The Analyst is a bench-top centrifugal clinical chemistry analyzer. In addition, Hemagen has entered into agreements to distribute a hematology analyzer and an electrolyte and blood gas analyzer to complement the AnalystŪ. [SEC Filing 10-KSB 12-31-07]
|
| |
|
Description:
Hemagen Diagnostics, a biotechnology company, develops, manufactures, and markets various proprietary medical diagnostic test kits worldwide.
|
| |
|
Officers:
William P. Hales (Pres., CEO & Dir.); Catherine M. Davidson (CFO); Alan S. Cohen (Dir.); Richard W. Edwards (Dir.); Edward T. Lutz (Dir.)
|
| |
|
Auditor:
Stegman & Company
|
| |
|
Securities:
Common Stock-Symbol HMGN.OB; OTC BB;
15,225,281 common shares outstanding as of December 17, 2007.
|
| |
| |
| |
| return to main page |
|
|
